RVL Pharma (NASDAQ:RVLP) Rises on Mulling  A Strategic Transaction
Market News

RVL Pharma (NASDAQ:RVLP) Rises on Mulling  A Strategic Transaction

Shares of specialty pharmaceutical company RVL Pharmaceuticals (NASDAQ:RVLP) are on the rise today on a disclosure that with the blessings of its Board, RVLP  has been evaluating certain strategic alternatives.

This includes talks on a potential acquisition of a specific counterparty in an all-stock deal as well as funding discussions for the combined entity.

At present, RVLP is focused on the commercialization of Upneeq for the treatment of acquired blepharoptosis and a strategic deal could lead to a diversified aesthetics company.

Overall, the Street has a $3 consensus price target on RVLP alongside a Moderate Buy consensus rating. Today’s price gains come after a nearly 52.1% drop in RVLP shares over the past six months.

Read full Disclosure

Related Articles
TheFlyFour new option listings and nineteen option delistings on October 24th
TheFlyRVL Pharmaceuticals announces prepackaged reorganization of certain U.S. units
TheFlyRVL Pharmaceuticals files to sell 11.87M shares of common stock for holders
Go Ad-Free with Our App